Take Home Message A combined prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT)–magnetic resonance imaging (MRI) model improved extraprostatic extension prediction in development but showed similar performance to MRI in external validation. The added value of PSMA PET/CT a...
V. Sweere, A. B. Bruins Slot, J. Heetman et al.· European Urology Open Scienc...· 0 citations
Organized, risk-adapted pathways integrating PSA, MRI, biomarkers, and baseline risk may better preserve early-detection benefits while reducing overdiagnosis and inequity.
R. Bernardino, David-Dan Nguyen, Sigrid V. Carlsson et al.· Prostate Cancer and Prostati...· 0 citations
CONTEXT
There are substantial regional differences in prostate cancer (PCa) epidemiology reflecting differences in risk factors, screening, management, and access to care.
OBJECTIVE
To assess geographical differences and temporal trends in PCa incidence and mortality and PCa risk factors.
EVIDENCE ACQUISITION
Estim...
G. Gandaglia, A. Weiner, A. Briganti et al.· European Urology· 0 citations
Comprehensive data on PSMA expression dynamics are still needed before this approach can be implemented in routine clinical practice, but the potential to personalize treatment strategies depending on treatment response is held.
J. le Guevelou, M. Bauckneht, T. Soeterik et al.· European Urology Open Scienc...· 0 citations
Population-based observations indicate that cryotherapy is associated with a higher risk of CSM compared with EBRT in these patients, and univariable competing risks regression models tested for CSM differences after accounting for other-cause mortality (OCM) as a competing event.
L. Quarta, M. Petix, M. Filzmayer et al.· World journal of urology· 0 citations
This retrospective study uses data from the National Cancer Database to examine patterns and temporal trends in use of focal therapy for prostate cancer in US cancer centers; characterize inappropriate use in low-, high-, or very–high-risk disease; and describe intermediate-risk use.
A. Cosenza, David-Dan Nguyen, Z. Qian et al.· Journal of the American Medi...· 1 citation
INTRODUCTION
Focal therapy (FT) in high-risk or very high-risk prostate cancer (CaP) is not guideline-recommended. However, it may be occasionally used, but its effect on cancer-specific mortality (CSM) relative to standard treatment options such as radical prostatectomy (RP) is unknown and was addressed in the present...
L. Quarta, M. Petix, M. Filzmayer et al.· Urologic oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.